Treace Announces First Surgical Cases Utilizing the SpeedAkin™ Anatomic Compression ImplantPONTE VEDRA, Fla., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced the successful completion of the first cases utilizing its SpeedAkin™ Anatomic Compression Implant.
Treace Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2024 RevenuePONTE VEDRA, Fla., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced its preliminary, unaudited fourth quarter and full-year 2024 results.
The Law Offices of Frank R. Cruz Continues Its Investigation of Treace Medical Concepts, Inc. (TMCI) on Behalf of Investors
The Law Offices of Frank R. Cruz continues its investigation on behalf of Treace Medical Concepts, Inc. (“Treace” or the “Company”) (
NASDAQTMCI) investors concerning the Company and its officers’ possible violations of federal securities laws.
Treace to Present at 43rd Annual J.P. Morgan Healthcare ConferencePONTE VEDRA, Fla., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that John T. Treace, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, beginning at approximately 9:00 am PT.
Treace Medical Concepts Inc Is Being Investigated For Securities Law Violations And Impacted Investors Are Invited To Contact The Schall Law FirmLOS ANGELES, CA / ACCESSWIRE / December 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company") (
NASDAQTMCI) for violations of the securities laws.
Treace Announces First Surgical Cases Utilizing the SpeedPlate™ MicroQuad™ ImplantPONTE VEDRA, Fla., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced the successful completion of the first cases utilizing SpeedPlate™ MicroQuad™ implants.
The Schall Law Firm Urges Shareholder Participation In An Inquiry Into Treace Medical Concepts, Inc. For Securities FraudLOS ANGELES, CA / ACCESSWIRE / December 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company") (
NASDAQTMCI) for violations of the securities laws.
Treace Medical Concepts Inc Is Being Investigated For Securities Law Violations And Investors With Losses Are Invited To Contact The Schall Law FirmLOS ANGELES, CA / ACCESSWIRE / December 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company") (
NASDAQTMCI) for violations of the securities laws.
The Schall Law Firm Encourages Stockholder Participation In An Inquiry Into Treace Medical Concepts, Inc. For Securities FraudLOS ANGELES, CA / ACCESSWIRE / December 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company") (
NASDAQTMCI) for violations of the securities laws.
Treace Medical Concepts Inc Is Being Investigated For Securities Law Violations And Affected Investors Are Invited To Contact The Schall Law FirmLOS ANGELES, CA / ACCESSWIRE / December 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company") (
NASDAQTMCI) for violations of the securities laws.
Treace Announces First Cases Utilizing RedPoint™ Intelliguide™ Patient Specific Instrumentation with the Adductoplasty® System for Correction of Midfoot DeformitiesPONTE VEDRA, Fla., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced the successful completion of the first cases combining IntelliGuide™ PSI technology with the Adductoplasty® System for a CT-based, patient specific correction personalized to the patient’s unique midfoot deformity.
Treace Appoints Guy Guglielmino as Chief Commercial OfficerPONTE VEDRA, Fla., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that Guy Guglielmino joined the Company as Chief Commercial Officer. In this new position, Mr. Guglielmino will lead Treace’s commercial efforts and play a pivotal role in driving the Company’s next phase of rapid innovation, strategic product commercialization, and growth.
Treace Announces Participation at Stifel 2024 Healthcare ConferencePONTE VEDRA, Fla., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer, will participate in a fireside chat at the Stifel 2024 Healthcare Conference on Tuesday, November 19, 2024, beginning at approximately 8:00 am ET.
TREACE ALERT: Bragar Eagel & Squire, P.C. is Investigating Treace Medical Concepts, Inc. on Behalf of Treace Stockholders and Encourages Investors to Contact the FirmNEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Treace Medical Concepts, Inc. (“Treace” or the “Company”) (
NASDAQTMCI) on behalf of Treace stockholders. Our investigation concerns whether Treace has violated the federal securities laws and/or engaged in other unlawful business practices.
Treace Medical Concepts Reports Third Quarter 2024 Financial ResultsPONTE VEDRA, Fla., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today reported financial results for the third quarter ended September 30, 2024.
Treace Announces Participation in the UBS Global Healthcare ConferencePONTE VEDRA, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer, will participate in a fireside chat at the UBS Global Healthcare Conference on Tuesday, November 12, 2024, beginning at approximately 11:45 am ET.
